Channing Der guides the Guardian through the history of the "Undruggable RAS Mutation."
Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions. An article by TARA HAELLE PUBLISHED August 03, 2018 The fact that JOHN MACLEOD'S colorectal cancer expresses a RAS gene mutation has limited his treatment options. - PHOTO BY KONNOR J … Continue reading ‘Cracking the Nut’ on RAS Mutations
UNC's Running RAScals (aka the Der Lab at UNC Lineberger & Friends) participated in this year’s PanCAN #PurpleStride run on Saturday, April 21st. This 5k run raises money to support the Pancreatic Cancer Action Network. The team, organized by Kirsten Bryant, raised $10,839 to support Pancreatic Cancer Research, coming in Fifth in overall fundraising! This was the Der Lab's fifth … Continue reading PurpleStride Raleigh-Durham 2018: Running RAScals
This article was posted on the Pancreatic Cancer Action Network on March 9, 2018 by Allison Rosenweig, PhD. KRAS protein structure, reproduced with permission from NCI, FNLCR About 95 percent of pancreatic cancer cases – and around 30 percent of all human cancers – have a mutation in a gene called RAS. The resulting mutated … Continue reading NPR Focuses on One of the Biggest Challenges in Pancreatic Cancer: KRAS
UNC Lineberger’s Channing Der, PhD, and colleagues have made new findings that could help researchers identify treatments for cancers with mutations in the RAS gene family, which are among the most highly mutated genes in cancer.
The Running RAScals (aka the Der Lab at UNC Lineberger & Friends) participated in this year’s PanCAN #PurpleStride run on Saturday. This 5k run raises money to support the Pancreatic Cancer Action Network. The team, organized by Kirsten Bryant, raised $12,998 to support Pancreatic Cancer Research, coming in Second in overall fundraising!
In the recently published review “Drugging Ras: Know your enemy” Bjoern Papke and Channing Der summarize the latest efforts in targeting the Ras oncogene. The review was part of the special review series “Frontiers in Cancer Therapy”. http://science.sciencemag.org/content/355/6330/1158
Mutant RAS-driven cancers are infamously resistant to chemotherapeutics. Reporting in Cell, Grabocka and Bar-Sagi (2016) demonstrate that when subjected to stress, mutant KRAS-dependent lipid production leads to upregulated stress granule formation. This confers not only cell-autonomous cytoprotection but also paracrine establishment of a stress-resistant tumor niche. Mutant RAS Calms Stressed-Out Cancer Cells. Bryant KL, Der CJ. Dev Cell. … Continue reading Kirsten Bryant authored a review in Cancer Cell, highlighting studies by Bar-Sagi and colleagues published in Cell.
Bjoern Papke, a postdoctoral research fellow in the Der lab, was recently awarded the Otto Hahn Medal from the Max Planck Society in Germany. The Otto Hahn Medal is given to junior scientists in recognition of their outstanding scientific achievements during their time as a PhD student. Bjoern did his PhD in the lab of … Continue reading Bjoern Papke awarded the Otto Hahn Medal
Dr. Channing Der was honored as this year's Emmanuel Farber Distinguished Visiting Lecturer. This special talk is a part of the University of Toronto Laboratory Medicine & Pathobiology weekly seminar. Dr. Der spoke about Targeting RAS for cancer treatment. See below for the history of this special lectureship. History of the Farber Distinguished Visiting Lecture … Continue reading Der honored with Emmanuel Farber Distinguished Visiting Lectureship